(NAS Colloquium) Genetic Engineering of Viruses and Viral Vectors

1 Contents; 2 Genetic engineering of viruses and of virus vectors: A preface; 3 Site-specific integration by adeno-associated virus; 4 Oncogenic potential of the adenovirus E4orf6 protein; 5 Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma; 6 The function of herpes simplex virus genes: A primer for genetic engineering of novel vectors; 7 The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors; 8 Replication-defective herpes simplex virus vectors for gene transfer in vivo; 9 A deletion mutant in the human cytomegalovirus gene encoding IEl 49laa is replication defective due to a failure in autoregulation; 10 Human cytomegalovirus U53 impairs transport and maturation of major histocompatibility complex class I heavy chains; 11 Epstein-Barr virus vectors for gene delivery to B lymphocytes; 12 Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety; 13 Applications of pox virus vectors to vaccination: An update; 14 Negative-strand RNA viruses: Genetic engineering and applications; 15 Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles; 16 Specific infection of CD4+ target cells by recombinant rabies virus pseudotypes carrying the HIV-1 envelope spike protein; 17 Alphavirus-based expression vectors: Strategies and applications; 18 Early events in poliovirus infection: Virus-receptor interactions; 19 Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector; 20 Use of virion DNA as a cloning vector for the construction of mutant and recombinant herpesviruses; 21 Development of HIV vectors for anti-HIV gene therapy; 22 A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes; 23 Cell-surface receptors for retroviruses and implications for gene transfer; 24 Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease; 25 Fusigenic viral liposome for gene therapy in cardiovascular diseases